Replimune Group's skin cancer drug candidate has been rejected by the FDA for a second time. This regulatory setback follows previous scrutiny and raises questions about the drug's path to market.
Replimune Skin Cancer Drug Fails Second FDA Approval Attempt
biotechnologypharmaceuticalsdrug_approvalregulatory_risk
